HRP20100672T1 - Hcv ns5b inhibitori - Google Patents

Hcv ns5b inhibitori Download PDF

Info

Publication number
HRP20100672T1
HRP20100672T1 HR20100672T HRP20100672T HRP20100672T1 HR P20100672 T1 HRP20100672 T1 HR P20100672T1 HR 20100672 T HR20100672 T HR 20100672T HR P20100672 T HRP20100672 T HR P20100672T HR P20100672 T1 HRP20100672 T1 HR P20100672T1
Authority
HR
Croatia
Prior art keywords
cyclohexyl
benzazepine
carboxylic acid
indol
methyl
Prior art date
Application number
HR20100672T
Other languages
English (en)
Croatian (hr)
Inventor
P. Bergstrom Carl
W. Martin Scott
W. Hudyma Thomas
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20100672T1 publication Critical patent/HRP20100672T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
HR20100672T 2006-02-08 2007-02-07 Hcv ns5b inhibitori HRP20100672T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77139106P 2006-02-08 2006-02-08
PCT/US2007/061768 WO2007092888A2 (en) 2006-02-08 2007-02-07 Hcv ns5b inhibitors

Publications (1)

Publication Number Publication Date
HRP20100672T1 true HRP20100672T1 (hr) 2011-01-31

Family

ID=38234480

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100672T HRP20100672T1 (hr) 2006-02-08 2007-02-07 Hcv ns5b inhibitori

Country Status (17)

Country Link
US (1) US7456165B2 (https=)
EP (1) EP1987038B1 (https=)
JP (1) JP5147731B2 (https=)
KR (1) KR20080102161A (https=)
CN (1) CN101379066B (https=)
AT (1) ATE483712T1 (https=)
AU (1) AU2007211988B2 (https=)
CY (1) CY1111423T1 (https=)
DE (1) DE602007009646D1 (https=)
DK (1) DK1987038T3 (https=)
ES (1) ES2352574T3 (https=)
HR (1) HRP20100672T1 (https=)
NO (1) NO20083513L (https=)
PL (1) PL1987038T3 (https=)
PT (1) PT1987038E (https=)
SI (1) SI1987038T1 (https=)
WO (1) WO2007092888A2 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049622A1 (ja) * 2003-11-19 2005-06-02 Japan Tobacco Inc. ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456167B2 (en) * 2006-05-25 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) * 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) * 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) * 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
CN101903351B (zh) 2007-12-19 2014-09-10 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
US8119628B2 (en) * 2008-03-27 2012-02-21 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine HCV NS5B inhibitors
JP2011515486A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎の治療用化合物
KR20100124848A (ko) 2008-03-27 2010-11-29 브리스톨-마이어스 스큅 컴퍼니 방향족 헤테로시클릭 융합된 인돌로벤자디아제핀 ｈｃｖ ｎｓ5ｂ 억제제
WO2009120890A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine hcv ns5b inhibitors
US8133884B2 (en) 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
JP2012514605A (ja) 2009-01-07 2012-06-28 サイネクシス，インコーポレーテッド Ｈｃｖおよびｈｉｖ感染の治療への使用におけるシクロスポリン誘導体
WO2010093359A1 (en) * 2009-02-11 2010-08-19 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
CA2822357A1 (en) 2010-12-22 2012-06-28 Abbvie Inc. Hepatitis c inhibitors and uses thereof
EA201390988A1 (ru) 2010-12-30 2014-04-30 Энанта Фармасьютикалз, Инк. Фенантридиновые макроциклические ингибиторы сериновой протеазы вируса гепатита c
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN102276531A (zh) * 2011-05-30 2011-12-14 扬子江药业集团广州海瑞药业有限公司 一种甲磺酸非诺多泮的制备方法
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104447952A (zh) * 2014-12-11 2015-03-25 上海唐润医药科技有限公司 丙肝病毒蛋白酶抑制剂及其合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138109A1 (en) * 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
JP2006526011A (ja) * 2003-04-11 2006-11-16 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ（特に、ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ）のインヒビター
US20050119318A1 (en) * 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
EP1799679B1 (de) 2004-10-13 2008-01-23 Merck Patent GmbH Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs
WO2006046039A2 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors

Also Published As

Publication number Publication date
SI1987038T1 (sl) 2011-02-28
NO20083513L (no) 2008-10-14
DK1987038T3 (da) 2011-01-31
ATE483712T1 (de) 2010-10-15
DE602007009646D1 (de) 2010-11-18
ES2352574T3 (es) 2011-02-21
KR20080102161A (ko) 2008-11-24
CN101379066B (zh) 2011-08-03
WO2007092888A3 (en) 2007-10-11
EP1987038A2 (en) 2008-11-05
CY1111423T1 (el) 2015-08-05
JP5147731B2 (ja) 2013-02-20
WO2007092888A2 (en) 2007-08-16
CN101379066A (zh) 2009-03-04
PT1987038E (pt) 2010-12-09
AU2007211988B2 (en) 2012-02-02
JP2009526081A (ja) 2009-07-16
EP1987038B1 (en) 2010-10-06
US7456165B2 (en) 2008-11-25
PL1987038T3 (pl) 2011-03-31
AU2007211988A1 (en) 2007-08-16
US20070185083A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
HRP20100672T1 (hr) Hcv ns5b inhibitori
JP2009526081A5 (https=)
ES2449540T3 (es) Inhibidores macrocíclicos del virus de la hepatitis C
AU2020204571A1 (en) Pyrazole derivatives as sGC stimulators
TWI577672B (zh) Ｃ型肝炎病毒抑制劑
AR063213A1 (es) Amidas azociclicas fungicidas, composiciones fungicidas que las comprenden y su empleo en un metodo para controlar enfermedades en las plantas causadas por patogenos fungicos de la clase de los oomycetes.
WO2014014874A1 (en) Pyrazole derivatives which inhibit leukotriene production
CN103917541B (zh) 抗病毒化合物
ES2564906T3 (es) Inhibidores de NS5A del VHC
CN101648944A (zh) 病毒聚合酶抑制剂
WO2017191000A1 (en) Aromatic sulfonamide derivatives
WO2010111673A1 (en) Substituted bicyclic hcv inhibitors
KR20110131312A (ko) 융합된 고리 ｃ형 간염 억제제
CN103189371A (zh) 新颖丙型肝炎病毒抑制剂
JP2011521965A5 (https=)
JP6695335B2 (ja) ＲＯＲγｔのモジュレーターとしてのアミド置換チアゾール
KR20200081436A (ko) 파르네소이드 x 수용체 조정제로서의 알켄 화합물
CA2760746A1 (en) Isoxazole-pyrazole derivatives
JP2010535787A5 (https=)
JP2008504281A5 (https=)
AU2024219819A1 (en) N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides
JP2011520810A5 (https=)
CA2449578A1 (en) Pyrrolidine oxadiazole- and thiadiazole derivatives
EP3972590A1 (en) Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
JP6069492B2 (ja) Ｃ型肝炎ウイルス阻害剤